FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220948924> ?p ?o ?g. }

• W4220948924 abstract "The pathogenesis of autism spectrum disorder (ASD) is under investigation and one of the main alterations relates to the metabolic and inflammatory system dysfunctions. Indeed, based on a possible deficit of omega-3 fatty acids (FAs) of patients with ASD and looking for an anti-inflammatory effect, dietary supplements with omega-3 fatty acids have been proposed. We aimed to evaluate differences in plasma and erythrocyte FA profiles and plasma cytokines in patients with infantile ASD after supplementation with docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids or placebo and both compared at baseline with a reference healthy group.A double-blind, randomized placebo-controlled intervention with DHA/EPA for 6 months was carried out in 54 children between 2 and 6 years diagnosed with ASD. They were selected and randomly assigned into two groups: 19 children received 800 mg/day of DHA and 25 mg/day of EPA, or placebo. In addition, another reference group of 59 healthy children of the same age was included. Plasma lipids and cytokines, and FA profiles in plasma and erythrocytes were measured at baseline and after 6 months of treatment in ASD children, and at baseline in the reference group.There were no differences in demographic, anthropometric characteristics, and omega-3 intake between the healthy reference group and the ASD children at baseline. Children with ASD showed the higher plasma percentages of palmitic acid and total saturated FA and lower total omega-6 polyunsaturated FA (PUFA) compared with healthy children. An increased level of DHA and reduced EPA level in erythrocytes were detected in the ASD group vs. the reference group. After 6 months of treatment, the ASD group that received DHA enriched product significantly increased the plasma and erythrocyte percentages of DHA, but no differences were observed in the clinical test scores and other parameters as plasma cytokines between the two groups of ASD related to the intervention.Spanish children with ASD exhibit an appropriate omega-3 FA status in plasma and erythrocytes. Neither a clinical improvement of ASD children nor a better anti-inflammatory or fatty acid state has been found after an intervention with DHA/EPA for 6 months. So, the prescription of n-3 LC-PUFA and other dietary supplements in ASD should be only indicated after a confirmed alteration of FA metabolism or omega-3 LC-PUFA deficiency evaluated by specific erythrocyte FA.[www.ClinicalTrials.gov], identifier [NCT03620097]." @default.
• W4220948924 created "2022-04-03" @default.
• W4220948924 creator A5004170966 @default.
• W4220948924 creator A5016707862 @default.
• W4220948924 creator A5021038143 @default.
• W4220948924 creator A5021635121 @default.
• W4220948924 creator A5037240320 @default.
• W4220948924 creator A5049593983 @default.
• W4220948924 creator A5057641249 @default.
• W4220948924 creator A5071071401 @default.
• W4220948924 creator A5078523805 @default.
• W4220948924 date "2022-03-29" @default.
• W4220948924 modified "2023-10-18" @default.
• W4220948924 title "Docosahexaenoic and Eicosapentaenoic Intervention Modifies Plasma and Erythrocyte Omega-3 Fatty Acid Profiles But Not the Clinical Course of Children With Autism Spectrum Disorder: A Randomized Control Trial" @default.
• W4220948924 cites W1596389679 @default.
• W4220948924 cites W1885027203 @default.
• W4220948924 cites W1964438752 @default.
• W4220948924 cites W1965796291 @default.
• W4220948924 cites W1966991669 @default.
• W4220948924 cites W1976498610 @default.
• W4220948924 cites W1993385646 @default.
• W4220948924 cites W1999258255 @default.
• W4220948924 cites W2009214635 @default.
• W4220948924 cites W2011890655 @default.
• W4220948924 cites W2025802167 @default.
• W4220948924 cites W2026281867 @default.
• W4220948924 cites W2029654118 @default.
• W4220948924 cites W2062551414 @default.
• W4220948924 cites W2069364515 @default.
• W4220948924 cites W2076898547 @default.
• W4220948924 cites W2077233786 @default.
• W4220948924 cites W2095607495 @default.
• W4220948924 cites W2098825532 @default.
• W4220948924 cites W2103983659 @default.
• W4220948924 cites W2117233879 @default.
• W4220948924 cites W2137325725 @default.
• W4220948924 cites W2140405768 @default.
• W4220948924 cites W2142056742 @default.
• W4220948924 cites W2144446993 @default.
• W4220948924 cites W2145076716 @default.
• W4220948924 cites W2152449622 @default.
• W4220948924 cites W2164294518 @default.
• W4220948924 cites W2165784158 @default.
• W4220948924 cites W2188810192 @default.
• W4220948924 cites W2206459738 @default.
• W4220948924 cites W2206567631 @default.
• W4220948924 cites W2522829059 @default.
• W4220948924 cites W2539340515 @default.
• W4220948924 cites W2565218888 @default.
• W4220948924 cites W2586514492 @default.
• W4220948924 cites W2589793208 @default.
• W4220948924 cites W2756340017 @default.
• W4220948924 cites W2757140893 @default.
• W4220948924 cites W2761424918 @default.
• W4220948924 cites W2775652281 @default.
• W4220948924 cites W2789985381 @default.
• W4220948924 cites W2790725217 @default.
• W4220948924 cites W2793215941 @default.
• W4220948924 cites W2799421848 @default.
• W4220948924 cites W2799526721 @default.
• W4220948924 cites W2802053593 @default.
• W4220948924 cites W2890644018 @default.
• W4220948924 cites W2893521709 @default.
• W4220948924 cites W2973684037 @default.
• W4220948924 cites W2982007797 @default.
• W4220948924 cites W2984576261 @default.
• W4220948924 cites W3010542713 @default.
• W4220948924 cites W3043056273 @default.
• W4220948924 cites W3082774434 @default.
• W4220948924 cites W3097684303 @default.
• W4220948924 cites W3128843431 @default.
• W4220948924 cites W3133961386 @default.
• W4220948924 cites W3207106718 @default.
• W4220948924 cites W40940716 @default.
• W4220948924 cites W414781422 @default.
• W4220948924 doi "https://doi.org/10.3389/fnut.2022.790250" @default.
• W4220948924 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35425788" @default.
• W4220948924 hasPublicationYear "2022" @default.
• W4220948924 type Work @default.
• W4220948924 citedByCount "4" @default.
• W4220948924 countsByYear W42209489242022 @default.
• W4220948924 countsByYear W42209489242023 @default.
• W4220948924 crossrefType "journal-article" @default.
• W4220948924 hasAuthorship W4220948924A5004170966 @default.
• W4220948924 hasAuthorship W4220948924A5016707862 @default.
• W4220948924 hasAuthorship W4220948924A5021038143 @default.
• W4220948924 hasAuthorship W4220948924A5021635121 @default.
• W4220948924 hasAuthorship W4220948924A5037240320 @default.
• W4220948924 hasAuthorship W4220948924A5049593983 @default.
• W4220948924 hasAuthorship W4220948924A5057641249 @default.
• W4220948924 hasAuthorship W4220948924A5071071401 @default.
• W4220948924 hasAuthorship W4220948924A5078523805 @default.
• W4220948924 hasBestOaLocation W42209489241 @default.
• W4220948924 hasConcept C126322002 @default.
• W4220948924 hasConcept C134018914 @default.
• W4220948924 hasConcept C142724271 @default.
• W4220948924 hasConcept C168563851 @default.
• W4220948924 hasConcept C19038510 @default.
• W4220948924 hasConcept C204787440 @default.
• W4220948924 hasConcept C27081682 @default.

• next